DDIT3 and diffuse large B-cell lymphoma: A subgroup network meta-analysis revealed improved hazard ratios in patients with untreated activated B-cell-like (ABC) DLBCL, an aggressive and generally treatment-resistant subtype, who were treated with Pola-R-CHP when compared to other regimens, including R-CHOP plus bortezomib (HR: 0.52, p = 0.02), R-CHOP plus ibrutinib (HR: 0.43, p = 0.001), R-CHOP plus lenalidomide (HR: 0.51, p = 0.009), obinutuzumab-CHOP (HR: 0.46, p = 0.008), and R-CHOP (HR: 0.40, p < 0.001) [31].